Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Out of sight, out of mind. A new study suggests a common eye condition could be quietly masking one of the only early warning ...

The earliest symptoms of bladder cancer may go unnoticed by patients with colorblindness or similar color vision deficiencies ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

By Dr. Sanchari Sinha Dutta, Ph.D. A large electronic health record study suggests that difficulty recognizing painless blood ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Recognizing the sight of blood in urine, the most common first sign of bladder cancer, is often the impetus that leads people ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...